These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 38161537)

  • 1. The Evolving Role of Vericiguat in Patients With Chronic Heart Failure.
    Dies RM; Jackson CN; Flanagan CJ; Sinnathamby ES; Spillers NJ; Potharaju P; Singh N; Varrassi G; Ahmadzadeh S; Shekoohi S; Kaye AD
    Cureus; 2023 Dec; 15(12):e49782. PubMed ID: 38161537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS; Tolppanen H
    Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vericiguat for the treatment of heart failure with reduced ejection fraction.
    Siddiqi AK; Greene SJ; Fudim M; Mentz RJ; Butler J; Khan MS
    Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):245-257. PubMed ID: 36881733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.
    Hulot JS; Trochu JN; Donal E; Galinier M; Logeart D; De Groote P; Juillière Y
    Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.
    Campbell N; Kalabalik-Hoganson J; Frey K
    Ann Pharmacother; 2022 May; 56(5):600-608. PubMed ID: 34431706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging concepts in heart failure management and treatment: focus on vericiguat.
    Kaplinsky E; Perrone S; Barbagelata A
    Drugs Context; 2023; 12():. PubMed ID: 36660012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
    Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
    J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science.
    Trujillo ME; Ayalasomayajula S; Blaustein RO; Gheyas F
    Clin Transl Sci; 2023 Dec; 16(12):2458-2466. PubMed ID: 37997225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
    Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
    Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure.
    Sahana U; Wehland M; Simonsen U; Schulz H; Grimm D
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    Kang C; Lamb YN
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.
    Alsumali A; Lautsch D; Liu R; Patel D; Nanji S; Djatche LM
    Adv Ther; 2021 May; 38(5):2631-2643. PubMed ID: 33860924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction.
    Tran BA; Serag-Bolos ES; Fernandez J; Miranda AC
    J Pharm Pract; 2023 Aug; 36(4):905-914. PubMed ID: 35356844
    [No Abstract]   [Full Text] [Related]  

  • 15. Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications.
    Vannuccini F; Campora A; Barilli M; Palazzuoli A
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations.
    Kassis-George H; Verlinden NJ; Fu S; Kanwar M
    Ther Clin Risk Manag; 2022; 18():315-322. PubMed ID: 35386181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction.
    Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M
    Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States.
    Khan MS; Xu H; Fonarow GC; Lautsch D; Hilkert R; Allen LA; DeVore AD; Alhanti B; Yancy CW; Albert NM; Butler J; Greene SJ
    JACC Heart Fail; 2023 Feb; 11(2):211-223. PubMed ID: 36754528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat.
    Fritsch A; Meyer M; Blaustein RO; Trujillo ME; Kauh E; Roessig L; Boettcher M; Becker C
    Clin Pharmacokinet; 2024 Jun; 63(6):751-771. PubMed ID: 38916717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.
    Butler J; Usman MS; Anstrom KJ; Blaustein RO; Bonaca MP; Ezekowitz JA; Freitas C; Lam CSP; Lewis EF; Lindenfeld J; McMullan CJ; Mentz RJ; O'Connor C; Rosano GMC; Saldarriaga CI; Senni M; Udelson J; Voors AA; Zannad F
    Eur J Heart Fail; 2022 Nov; 24(11):2029-2036. PubMed ID: 36250238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.